Sign in Subscribe

liquid-biopsy

A collection of 68 issues

Updated ACS Guideline Addresses Blood Tests for Colorectal Cancer Screening

Skip to content The CRC Digest ▪ SCREENING Updated ACS Guideline Addresses Blood Tests for Colorectal Cancer Screening A JAMA article by Rubin discusses what an updated ACS guideline says about blood-based screening tests for colorectal cancer. (JAMA) This content is informational only and does not constitute medical advice. Always consult

Multitarget stool DNA test shows promise over standard FIT screening

Skip to content The CRC Digest ▪ SCREENING Multitarget stool DNA test shows promise over standard FIT screening A systematic review found that multitarget stool DNA (mt-sDNA) testing emerged as a promising alternative to faecal immunochemical test (FIT) for detecting colorectal neoplasms, particularly given FIT's low sensitivity for advanced

AHN researchers help develop blood test that detects colorectal cancer and high-risk polyps

Skip to content The CRC Digest ▪ SCREENING AHN researchers help develop blood test that detects colorectal cancer and high-risk polyps Researchers at Allegheny Health Network contributed to development of a blood-based screening test capable of detecting both colorectal cancer and high-risk polyps. (Beaver County Radio) This content is informational only

Blood test shows promise for detecting advanced adenomas and colorectal cancer

Skip to content The CRC Digest ▪ SCREENING Blood test shows promise for detecting advanced adenomas and colorectal cancer The DENEB study developed and evaluated a novel blood-based assay designed to detect both advanced adenomas and colorectal cancer, addressing a key limitation of current blood tests by targeting premalignant lesions essential

Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease

Skip to content The CRC Digest ▪ RESEARCH Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease A translational science review in JAMA reports that circulating tumor DNA (ctDNA) sequencing can identify gene variants to inform treatment selection in colorectal cancer, and that detecting ctDNA after curative intent therapy correlates

ctDNA-Guided Treatment Decisions Show Mixed Results in Stage II and III Colon Cancer

Skip to content The CRC Digest ctDNA-Guided Treatment Decisions Show Mixed Results in Stage II and III Colon Cancer DYNAMIC-III found that escalation in ctDNA-positive stage III patients did not improve outcomes. (EClinicalMedicine) This content is informational only and does not constitute medical advice. Always consult your oncologist or care

ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection

Skip to content The CRC Digest ◇ RESEARCH ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection A review of circulating tumor DNA in GI cancers found that while postoperative ctDNA positivity identifies high-risk patients, recent trials show mixed results: DYNAMIC-III showed escalation in ctDNA-positive stage III disease

AI method for classifying pathology whole slide images using self-distillation technique

Skip to content The CRC Digest ◇ RESEARCH AI method for classifying pathology whole slide images using self-distillation technique Researchers developed a phenotypic self-distillation approach to classify whole slide images in colorectal cancer, addressing limitations of current attention mechanisms in Multiple Instance Learning. (Pathology Research and Practice) This content is informational

FDA approves second blood test to help close colorectal cancer screening gap

Skip to content The CRC Digest ● REGULATORY FDA approves second blood test to help close colorectal cancer screening gap The FDA has approved a second blood-based screening test for colorectal cancer, expanding options for patients who may avoid traditional colonoscopy. (AOL.com) This content is informational only and does not

Stool DNA Tests Offer Higher Sensitivity but Lower Specificity Than FIT

Skip to content The CRC Digest Stool DNA Tests Offer Higher Sensitivity but Lower Specificity Than FIT Multitarget stool DNA tests show higher sensitivity for colorectal cancer and advanced adenomas than FIT, but with lower specificity and higher costs; further evidence is needed on long-term effectiveness and economic sustainability. (Clinical